How mass spectrometric interrogation of MHC class I ligandomes has advanced our understanding of immune responses to viruses.
暂无分享,去创建一个
[1] S. Madhi,et al. Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus , 2023, BioDrugs.
[2] E. Walsh,et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. , 2023, The New England journal of medicine.
[3] H. Kestler,et al. The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination , 2023, British Journal of Cancer.
[4] Isaac B. Woodhouse,et al. Novel canonical and non-canonical viral antigens extend current targets for immunotherapy of HPV-driven cervical cancer , 2023, iScience.
[5] G. Atwal,et al. Proteogenomic identification of Hepatitis B virus (HBV) genotype-specific HLA-I restricted peptides from HBV-positive patient liver tissues , 2022, Frontiers in Immunology.
[6] Tobias N. Hoheisel,et al. Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity , 2022, iScience.
[7] R. D. de Man,et al. Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma , 2022, JHEP reports : innovation in hepatology.
[8] A. Bertoletti,et al. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic , 2022, Immunity.
[9] P. P. Corsetti,et al. Epitope identification of SARS-CoV-2 structural proteins using in silico approaches to obtain a conserved rational immunogenic peptide , 2022, ImmunoInformatics.
[10] M. MacCoss,et al. Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs , 2021, Proceedings of the National Academy of Sciences.
[11] Yoon Ki Kim,et al. A high-resolution temporal atlas of the SARS-CoV-2 translatome and transcriptome , 2021, Nature Communications.
[12] T. Elliott,et al. Immunopeptidomic analysis of influenza A virus infected human tissues identifies internal proteins as a rich source of HLA ligands , 2021, bioRxiv.
[13] N. Ternette,et al. Know thy immune self and non‐self: Proteomics informs on the expanse of self and non‐self, and how and where they arise , 2021, Proteomics.
[14] A. Purcell,et al. Direct identification of HLA‐presented CD8 T cell epitopes from transmitted founder HIV‐1 variants , 2021, Proteomics.
[15] Chih-Chiang Tsou,et al. Pitfalls in HLA Ligandomics—How to Catch a Li(e)gand , 2021, Molecular & cellular proteomics : MCP.
[16] Ansuman T. Satpathy,et al. Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics , 2021, Cell Reports.
[17] S. Carr,et al. Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics , 2021, Nature Communications.
[18] Jennifer G. Abelin,et al. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs , 2021, Cell.
[19] I. Ulitsky,et al. SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis , 2021, Nature.
[20] C. Brander,et al. Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses. , 2021, Cell reports.
[21] B. Haynes,et al. Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells , 2021, Cell Reports.
[22] S. Mallal,et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.
[23] Sri H. Ramarathinam,et al. Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and aid for immunotherapy design , 2020, Nature Communications.
[24] M. Bruno,et al. The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design , 2020, Vaccines.
[25] R. Aebersold,et al. Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome , 2020, Journal of proteome research.
[26] V. Thiel,et al. Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.
[27] G. MacBeath,et al. Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein , 2020, Immunity.
[28] H. Rammensee,et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.
[29] P. Sopp,et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.
[30] P. Doherty,et al. Suboptimal SARS-CoV-2−specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype , 2020, Proceedings of the National Academy of Sciences.
[31] C. Brander,et al. In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction , 2020, PLoS pathogens.
[32] G. A. Efimov,et al. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors , 2020, Immunity.
[33] F. Castiglione,et al. A candidate multi-epitope vaccine against SARS-CoV-2 , 2020, Scientific Reports.
[34] Xiang-rong Song,et al. Ex vivo pulsed dendritic cell vaccination against cancer , 2020, Acta Pharmacologica Sinica.
[35] M. Tay,et al. The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.
[36] C. Ye,et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. , 2019, Journal of hepatology.
[37] G. Learn,et al. Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8+ T cells in HIV-1 infection , 2019, Proceedings of the National Academy of Sciences.
[38] D. Tscharke,et al. Quantification of epitope abundance reveals the effect of direct and cross-presentation on influenza CTL responses , 2019, Nature Communications.
[39] David F. Boyd,et al. Human CD8+ T cell cross-reactivity across influenza A, B and C viruses , 2019, Nature Immunology.
[40] Bjoern Peters,et al. Most viral peptides displayed by class I MHC on infected cells are immunogenic , 2019, Proceedings of the National Academy of Sciences.
[41] Ilan Beer,et al. Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome* , 2018, Molecular & Cellular Proteomics.
[42] M. Nielsen,et al. Predicted MHC peptide binding promiscuity explains MHC class I ‘hotspots’ of antigen presentation defined by mass spectrometry eluted ligand data , 2018, Immunology.
[43] Sri H. Ramarathinam,et al. Identification of Native and Posttranslationally Modified HLA‐B*57:01‐Restricted HIV Envelope Derived Epitopes Using Immunoproteomics , 2018, Proteomics.
[44] Mathieu Courcelles,et al. Comparison of the MHC I Immunopeptidome Repertoire of B‐Cell Lymphoblasts Using Two Isolation Methods , 2018, Proteomics.
[45] Martin R Larsen,et al. A Targeted LC‐MS Strategy for Low‐Abundant HLA Class‐I‐Presented Peptide Detection Identifies Novel Human Papillomavirus T‐Cell Epitopes , 2018, Proteomics.
[46] P. Borrow,et al. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows , 2018, Front. Immunol..
[47] P. Bhattarakosol,et al. Elevated HPV16 E1 Expression Is Associated with Cervical Cancer Progression , 2018, Intervirology.
[48] Ashwini Naik,et al. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution , 2017, Nature.
[49] Markus Müller,et al. ‘Hotspots’ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization , 2017, Front. Immunol..
[50] Sri H. Ramarathinam,et al. MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape , 2017, Nature Structural &Molecular Biology.
[51] P. Kloetzel,et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides , 2016, Science.
[52] D. Busch,et al. CD8+ T cells of Listeria monocytogenes‐infected mice recognize both linear and spliced proteasome products , 2016, European journal of immunology.
[53] M. Nielsen,et al. Defining the HLA class I‐associated viral antigen repertoire from HIV‐1‐infected human cells , 2015, European journal of immunology.
[54] I. Hoof,et al. Measles Virus Epitope Presentation by HLA: Novel Insights into Epitope Selection, Dominance, and Microvariation , 2015, Front. Immunol..
[55] Elisa Pappalardo,et al. Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells , 2015, Journal of Virology.
[56] Søren Buus,et al. Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding , 2015, eLife.
[57] D. Tscharke,et al. Simultaneous Quantification of Viral Antigen Expression Kinetics Using Data-Independent (DIA) Mass Spectrometry* , 2015, Molecular & Cellular Proteomics.
[58] Guang Lan Zhang,et al. Physical detection of influenza A epitopes identifies a stealth subset on human lung epithelium evading natural CD8 immunity , 2015, Proceedings of the National Academy of Sciences.
[59] Daniel López,et al. The Viral Transcription Group Determines the HLA Class I Cellular Immune Response Against Human Respiratory Syncytial Virus* , 2015, Molecular & Cellular Proteomics.
[60] L. Jensen,et al. Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.
[61] Peter A van Veelen,et al. Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes. , 2014, Journal of proteomics.
[62] Christian Brander,et al. Direct Interrogation of Viral Peptides Presented by the Class I HLA of HIV-Infected T Cells , 2014, Journal of Virology.
[63] Matthew E Monroe,et al. In-source fragmentation and the sources of partially tryptic peptides in shotgun proteomics. , 2013, Journal of Proteome Research.
[64] Anthony W. Purcell,et al. Kinetics of Antigen Expression and Epitope Presentation during Virus Infection , 2013, PLoS pathogens.
[65] Sébastien Lemieux,et al. MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. , 2012, Blood.
[66] Volker Brass,et al. Identification of Naturally Processed Hepatitis C Virus-Derived Major Histocompatibility Complex Class I Ligands , 2012, PloS one.
[67] R. Berkowitz,et al. Direct Identification of an HPV-16 Tumor Antigen from Cervical Cancer Biopsy Specimens , 2011, Front. Immun..
[68] M. Ramos,et al. Unusual viral ligand with alternative interactions is presented by HLA‐Cw4 in human respiratory syncytial virus‐infected cells , 2011, Immunology and cell biology.
[69] Ilan Beer,et al. Soluble plasma HLA peptidome as a potential source for cancer biomarkers , 2010, Proceedings of the National Academy of Sciences.
[70] D. Keskin,et al. A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on Human Papillomavirus 16-transformed HLA-A2+ Epithelial Cancers , 2010, The Journal of Biological Chemistry.
[71] Ilan Beer,et al. Multiple, Non-conserved, Internal Viral Ligands Naturally Presented by HLA-B27 in Human Respiratory Syncytial Virus-infected Cells* , 2010, Molecular & Cellular Proteomics.
[72] M. Taneichi,et al. Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A*0201 transgenic mice , 2009, Vaccine.
[73] G. Air,et al. HLA class I molecules consistently present internal influenza epitopes , 2009, Proceedings of the National Academy of Sciences.
[74] Bin Li,et al. HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition , 2008, Journal of Virology.
[75] A. Fiander,et al. HPV16 E629‐38‐specific T cells kill cervical carcinoma cells despite partial evasion of T‐cell effector function , 2008, International journal of cancer.
[76] E. Caron,et al. The MHC class I peptide repertoire is molded by the transcriptome , 2008, The Journal of experimental medicine.
[77] Hans-Georg Rammensee,et al. Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface*S , 2007, Molecular & Cellular Proteomics.
[78] Magdalini Moutaftsi,et al. A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.
[79] Albert J R Heck,et al. Stable Isotope Tagging of Epitopes , 2006, Molecular & Cellular Proteomics.
[80] J. Yewdell,et al. Making sense of mass destruction: quantitating MHC class I antigen presentation , 2003, Nature Reviews Immunology.
[81] Søren Brunak,et al. Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation , 2002, Journal of Virology.
[82] P. Roholl,et al. A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. , 2001, The Journal of general virology.
[83] C. Bony,et al. Identification in humans of HPV‐16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA‐B18 and determination of the HLA‐B18‐specific binding motif , 2000, European journal of immunology.
[84] C. Herberts,et al. A single naturally processed measles virus peptide fully dominates the HLA‐A*0201‐associated peptide display and is mutated at its anchor position in persistent viral strains , 2000, European journal of immunology.
[85] R. Phillips,et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. , 1996, AIDS research and human retroviruses.
[86] J. Yewdell,et al. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , 1996, Journal of immunology.
[87] J. Lieberman,et al. Three regions of HIV-1 gp160 contain clusters of immunodominant CTL epitopes. , 1996, Immunology letters.
[88] E. Padlan,et al. H-2Dd exploits a four residue peptide binding motif , 1993, The Journal of experimental medicine.
[89] K. Parker,et al. Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[90] S. Ceman,et al. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. , 1992, Science.
[91] E. Padlan,et al. Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex , 1992, The Journal of experimental medicine.
[92] William S. Lane,et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.
[93] P. A. Peterson,et al. Emerging principles for the recognition of peptide antigens by MHC class I molecules. , 1992, Science.
[94] A Sette,et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. , 1992, Science.
[95] R. Henderson,et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.
[96] A. Rudensky,et al. Sequence analysis of peptides bound to MHC class II molecules , 1991, Nature.
[97] E. Gilboa,et al. A frameshift mutation at the NH2 terminus of the nucleoprotein gene does not affect generation of cytotoxic T lymphocyte epitopes. , 1991, Journal of immunology.
[98] D. R. Madden,et al. Identification of self peptides bound to purified HLA-B27 , 1991, Nature.
[99] H. Rammensee,et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.
[100] S. Nathenson,et al. Isolation of an endogenously processed immunodominant viral peptide from the class I H–2Kb molecule , 1990, Nature.
[101] J. Rothbard,et al. Recognition of influenza virus proteins by cytotoxic T lymphocytes. , 1989, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[102] J. Yewdell,et al. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. , 1988, Science.
[103] T. Oltersdorf,et al. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. , 1987, The EMBO journal.
[104] B. Jordan,et al. H—2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide , 1986, Nature.
[105] A. McMichael,et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.
[106] J. Davey,et al. Cytotoxic T cells recognize fragments of the influenza nucleoprotein , 1985, Cell.
[107] G. Shearer,et al. Human cytotoxic T-cell responses to type A and type B influenza viruses can be restricted by different HLA antigens. Implications for HLA polymorphism and genetic regulation , 1980, The Journal of experimental medicine.
[108] R. Zinkernagel,et al. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytes choriomeningitis , 1974, Nature.
[109] R. Zinkernagel,et al. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system , 1974, Nature.
[110] P. Edman,et al. A method for the determination of amino acid sequence in peptides. , 1949, Archives of biochemistry.
[111] Ed van der Heeft,et al. Dynamics of measles virus protein expression are reflected in the MHC class I epitope display. , 2003, Molecular immunology.
[112] A. Townsend,et al. Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.
[113] E. Unanue,et al. Binding of immunogenic peptides to Ia histocompatibility molecules , 1985, Nature.